Sprint Bioscience AB Total Assets
Sprint Bioscience AB total assets. Based on the latest financial reports, Sprint Bioscience AB (SPRINT) holds total assets worth Skr118.97 Million SEK (≈ $12.80 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Sprint Bioscience AB market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Sprint Bioscience AB (2011–2025)
Total assets of Sprint Bioscience AB from 2011 to 2025. This chart illustrates how Sprint Bioscience AB's total assets have evolved over time, based on quarterly financial data. See Sprint Bioscience AB (SPRINT) stock price for real-time trading data and today's change.
Sprint Bioscience AB - Asset Composition Analysis
Sprint Bioscience AB Total Assets Breakdown (December 2025)
Sprint Bioscience AB total assets breakdown as of December 2025. Sprint Bioscience AB's total assets of Skr118.97 Million consist of 97.2% current assets and 2.8% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 92.7% |
| Accounts Receivable | Skr6.17 Million | 4.5% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr3.74 Million | 2.7% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Sprint Bioscience AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Sprint Bioscience AB working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sprint Bioscience AB's current assets represent 97.2% of total assets in 2025, an increase from 18.5% in 2011.
- Cash Position: Cash and equivalents constituted 92.7% of total assets in 2025, up from 2.6% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 4.5% of total assets.
Sprint Bioscience AB Competitors by Total Assets
Key competitors of Sprint Bioscience AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Sprint Bioscience AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.10 | 0.97 | 0.93 |
| Quick Ratio | 9.10 | 0.97 | 1.31 |
| Cash Ratio | 0.00 | 0.00 | 0.55 |
| Working Capital | Skr102.76 Million | Skr-943.00K | Skr-567.00K |
Sprint Bioscience AB - Advanced Valuation Insights
This section examines the relationship between Sprint Bioscience AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.04 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | 225.0% |
| Total Assets | Skr136.66 Million |
| Market Capitalization | $38.95 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sprint Bioscience AB's assets below their book value (0.28x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Sprint Bioscience AB's assets grew by 225.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sprint Bioscience AB (2011–2025)
The table below shows the annual total assets of Sprint Bioscience AB from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr136.66 Million ≈ $14.71 Million |
+224.96% |
| 2024-12-31 | Skr42.05 Million ≈ $4.53 Million |
-32.58% |
| 2023-12-31 | Skr62.38 Million ≈ $6.71 Million |
+66.69% |
| 2022-12-31 | Skr37.42 Million ≈ $4.03 Million |
-52.71% |
| 2021-12-31 | Skr79.14 Million ≈ $8.52 Million |
+136.94% |
| 2020-12-31 | Skr33.40 Million ≈ $3.59 Million |
+73.56% |
| 2019-12-31 | Skr19.24 Million ≈ $2.07 Million |
-67.54% |
| 2018-12-31 | Skr59.29 Million ≈ $6.38 Million |
+67.08% |
| 2017-12-31 | Skr35.48 Million ≈ $3.82 Million |
-28.34% |
| 2016-12-31 | Skr49.52 Million ≈ $5.33 Million |
+61.66% |
| 2015-12-31 | Skr30.63 Million ≈ $3.30 Million |
+21.82% |
| 2014-12-31 | Skr25.15 Million ≈ $2.71 Million |
+236.55% |
| 2013-12-31 | Skr7.47 Million ≈ $804.11K |
+73.72% |
| 2012-12-31 | Skr4.30 Million ≈ $462.87K |
+55.02% |
| 2011-12-31 | Skr2.77 Million ≈ $298.60K |
-- |
About Sprint Bioscience AB
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a d… Read more